Clinical Trials
3 trialsNCT07569926 2026-06-02
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
Blue Earth Diagnostics
Phase 4 Not yet recruiting
NCT02443571 2018-12-19
Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)
Blue Earth Diagnostics
Completed
NCT01176513 2014-02-14
GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer
GE Healthcare
Phase 2 Terminated